Gapping up
In reaction to strong earnings/guidance:
- ROKU +14.7% (sees Q1 revs above consensus but withdraws 2020 outlook), CNK +7.2% (to host call to discuss liquidity strategy), TMDX +6.8% (guides Q1 revs slightly above consensus; withdraws 2020 guidance), FAST +4%, AMRN +3.6% (guides Q1 revs above consensus), JNJ +3.5%, CONN +2.2%, JPM +0.8%
Other news:
- ABR +7.2% (provides COVID update)
- YETI +6.5% (to join S&P SmallCap 600)
- KRMD +5.3% (announces favorable ruling from US Federal Court of Appeals)
- MRNA +4.8% (announces opportunity of mRNA vaccines at its first vaccines day)
- VSTM +4.6% (announces presentation of clinical data)
- MDGL +4.3% (MAESTRO Phase 3 NASH trials continue without protocol modifications; new data demonstrate that reductions in liver fat achieved by resmetirom predict nash resolution and fibrosis reduction)
- ALNY +2.5% (receives Fast Track Designation for Vutrisiran)
- CALA +2.2% (provides update on business operations; on track to announce top-line CANTATA results this year)
- AAPL +1.6% (Apple mobility partner Physitrack partners with Physical Rehabilitation Network to deliver technology for remote patient engagement)
Analyst comments:
- BLPH +20.1% (initiated with Buy at Brookline Capital)
- TSLA +7.3% (upgraded to Neutral from Underperform at Credit Suisse)
- ZM +4.3% (initiated with an Overweight at Cantor Fitzgerald )
- PSXP +4.2% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ALSN +2.6% (upgraded to Strong Buy from Outperform at Raymond James)
- SUN +2.4% (upgraded to Buy from Hold at Jefferies)
- G +1% (upgraded to Overweight from Neutral at JP Morgan)